* using log directory ‘/data/blackswan/ripley/R/packages/tests-devel/cgdsr.Rcheck’
* using R Under development (unstable) (2022-04-01 r82052)
* using platform: x86_64-pc-linux-gnu (64-bit)
* using session charset: UTF-8
* checking for file ‘cgdsr/DESCRIPTION’ ... OK
* checking extension type ... Package
* this is package ‘cgdsr’ version ‘1.3.0’
* checking package namespace information ... OK
* checking package dependencies ... OK
* checking if this is a source package ... OK
* checking if there is a namespace ... OK
* checking for executable files ... OK
* checking for hidden files and directories ... OK
* checking for portable file names ... OK
* checking for sufficient/correct file permissions ... OK
* checking whether package ‘cgdsr’ can be installed ... OK
* checking package directory ... OK
* checking ‘build’ directory ... OK
* checking DESCRIPTION meta-information ... OK
* checking top-level files ... OK
* checking for left-over files ... OK
* checking index information ... OK
* checking package subdirectories ... OK
* checking R files for non-ASCII characters ... OK
* checking R files for syntax errors ... OK
* checking whether the package can be loaded ... OK
* checking whether the package can be loaded with stated dependencies ... OK
* checking whether the package can be unloaded cleanly ... OK
* checking whether the namespace can be loaded with stated dependencies ... OK
* checking whether the namespace can be unloaded cleanly ... OK
* checking loading without being on the library search path ... OK
* checking dependencies in R code ... OK
* checking S3 generic/method consistency ... OK
* checking replacement functions ... OK
* checking foreign function calls ... OK
* checking R code for possible problems ... OK
* checking Rd files ... OK
* checking Rd metadata ... OK
* checking Rd line widths ... OK
* checking Rd cross-references ... OK
* checking for missing documentation entries ... OK
* checking for code/documentation mismatches ... OK
* checking Rd \usage sections ... OK
* checking Rd contents ... OK
* checking for unstated dependencies in examples ... OK
* checking sizes of PDF files under ‘inst/doc’ ... OK
* checking installed files from ‘inst/doc’ ... OK
* checking files in ‘vignettes’ ... OK
* checking examples ... [3s/12s] OK
* checking examples with --run-donttest ... ERROR
Running examples in ‘cgdsr-Ex.R’ failed
The error most likely occurred in:
> ### Name: cgdsr-getMutationData
> ### Title: Get mutation data for cancer study
> ### Aliases: cgdsr-getMutationData getMutationData getMutationData.CGDS
>
> ### ** Examples
>
> # Create CGDS object
> mycgds = CGDS("http://www.cbioportal.org/")
>
> getCancerStudies(mycgds)
cancer_study_id
1 paac_jhu_2014
2 mel_tsam_liang_2017
3 all_stjude_2015
4 all_stjude_2016
5 aml_ohsu_2018
6 laml_tcga
7 laml_tcga_pub
8 laml_tcga_pan_can_atlas_2018
9 mnm_washu_2016
10 acyc_fmi_2014
11 acyc_jhu_2016
12 acyc_mda_2015
13 acyc_mgh_2016
14 acyc_mskcc_2013
15 acyc_sanger_2013
16 acc_2019
17 acbc_mskcc_2015
18 acc_tcga
19 acc_tcga_pan_can_atlas_2018
20 sarc_tcga_pub
21 ampca_bcm_2016
22 odg_msk_2017
23 bcc_unige_2016
24 blca_msk_tcga_2020
25 blca_mskcc_solit_2014
26 blca_mskcc_solit_2012
27 blca_plasmacytoid_mskcc_2016
28 blca_tcga_pub_2017
29 blca_bgi
30 blca_dfarber_mskcc_2014
31 blca_tcga
32 blca_tcga_pub
33 blca_tcga_pan_can_atlas_2018
34 lgg_tcga
35 lgg_tcga_pan_can_atlas_2018
36 gbm_mayo_pdx_sarkaria_2019
37 brca_hta9_htan_2022
38 brca_metabric
39 breast_msk_2018
40 brca_pareja_msk_2020
41 breast_alpelisib_2020
42 brca_mskcc_2019
43 brca_smc_2018
44 brca_bccrc_xenograft_2014
45 bfn_duke_nus_2015
46 brca_bccrc
47 brca_broad
48 brca_sanger
49 brca_tcga_pub2015
50 brca_tcga
51 brca_tcga_pub
52 brca_tcga_pan_can_atlas_2018
53 ccle_broad_2019
54 cellline_ccle_broad
55 msk_ch_ped_2021
56 msk_ch_2020
57 cesc_tcga_pan_can_atlas_2018
58 cesc_tcga
59 pan_origimed_2020
60 chol_icgc_2017
61 chol_msk_2018
62 chol_nccs_2013
63 chol_nus_2012
64 chol_tcga
65 chol_tcga_pan_can_atlas_2018
66 lcll_broad_2013
67 cll_broad_2015
68 cll_iuopa_2015
69 cllsll_icgc_2011
70 ccrcc_dfci_2019
71 coad_caseccc_2015
72 coad_cptac_2019
73 coadread_dfci_2016
74 coadread_genentech
75 coadread_tcga
76 coadread_tcga_pub
77 coadread_tcga_pan_can_atlas_2018
78 coadread_mskcc
79 crc_dd_2022
80 crc_apc_impact_2020
81 hccihch_pku_2019
82 cscc_dfarber_2015
83 cscc_hgsc_bcm_2014
84 cscc_ucsf_2021
85 ctcl_columbia_2015
86 pact_jhu_2011
87 desm_broad_2015
88 difg_glass_2019
89 dlbcl_dfci_2018
90 dlbc_broad_2012
91 dlbcl_duke_2017
92 dlbc_tcga_pan_can_atlas_2018
93 nhl_bcgsc_2013
94 crc_nigerian_2020
95 ucec_msk_2018
96 ucec_cptac_2020
97 esca_broad
98 esca_tcga_pan_can_atlas_2018
99 egc_trap_msk_2020
100 esca_tcga
101 stes_tcga_pub
102 escc_icgc
103 escc_ucla_2014
104 egc_mskcc_2020
105 es_iocurie_2014
106 gbc_msk_2018
107 gbc_shanghai_2014
108 egc_tmucih_2015
109 stad_oncosg_2018
110 gct_msk_2016
111 gct_msk_2020
112 gbm_cptac_2021
113 gbm_columbia_2019
114 gbm_tcga_pub2013
115 gbm_tcga_pub
116 gbm_tcga
117 gbm_tcga_pan_can_atlas_2018
118 glioma_msk_2018
119 glioma_mskcc_2019
120 hnsc_broad
121 hnsc_jhu
122 hnsc_tcga
123 hnsc_tcga_pub
124 hnsc_tcga_pan_can_atlas_2018
125 liad_inserm_fr_2014
126 hcc_mskimpact_2018
127 hcc_inserm_fr_2015
128 hgsoc_msk_2021
129 histiocytosis_cobi_msk_2019
130 all_stjude_2013
131 panet_shanghai_2013
132 chol_jhu_2013
133 ihch_mskcc_2020
134 ihch_msk_2021
135 ihch_ismms_2015
136 ihch_smmu_2014
137 brca_jup_msk_2020
138 kich_tcga_pub
139 kich_tcga
140 kich_tcga_pan_can_atlas_2018
141 kirc_bgi
142 ccrcc_irc_2014
143 kirc_tcga
144 kirc_tcga_pub
145 kirc_tcga_pan_can_atlas_2018
146 kirp_tcga
147 kirp_tcga_pan_can_atlas_2018
148 hcc_msk_venturaa_2018
149 lihc_amc_prv
150 lihc_riken
151 lihc_tcga
152 lihc_tcga_pan_can_atlas_2018
153 lgg_ucsf_2014
154 luad_broad
155 luad_cptac_2020
156 luad_mskcc_2020
157 luad_mskimpact_2021
158 luad_mskcc_2015
159 luad_msk_npjpo_2021
160 luad_oncosg_2020
161 luad_tcga
162 luad_tcga_pub
163 luad_tcga_pan_can_atlas_2018
164 luad_tsp
165 lung_smc_2016
166 lusc_cptac_2021
167 lusc_tcga
168 lusc_tcga_pub
169 lusc_tcga_pan_can_atlas_2018
170 dlbc_tcga
171 lymphoma_cellline_msk_2020
172 brca_mapk_hp_msk_2021
173 msk_met_2021
174 msk_impact_2017
175 msk_access_2021
176 mixed_allen_2018
177 mpnst_mskcc
178 mcl_idibips_2013
179 mbn_mdacc_2013
180 mbl_broad_2012
181 mbl_dkfz_2017
182 mbl_icgc
183 mbl_pcgp
184 mbl_sickkids_2016
185 skcm_broad_dfarber
186 mel_mskimpact_2020
187 skcm_mskcc_2014
188 skcm_tcga_pub_2015
189 lgggbm_tcga_pub
190 meso_tcga
191 meso_tcga_pan_can_atlas_2018
192 mbc_msk_2021
193 brca_igr_2015
194 breast_ink4_msk_2021
195 crc_msk_2017
196 egc_msk_2017
197 mel_dfci_2019
198 skcm_dfci_2015
199 skcm_vanderbilt_mskcc_2015
200 mel_ucla_2016
201 prad_mich
202 prad_su2c_2019
203 prad_su2c_2015
204 metastatic_solid_tumors_mich_2017
205 prad_mcspc_mskcc_2020
206 mixed_kunga_msk_2022
207 cfdna_msk_2019
208 mixed_cfdna_msk_2020
209 mm_broad
210 mds_tokyo_2011
211 mds_mskcc_2020
212 mpn_cimr_2013
213 cellline_nci60
214 npc_nusingapore
215 nbl_amc_2012
216 nbl_broad_2013
217 nbl_ucologne_2015
218 nepc_wcm_2016
219 nhl_bcgsc_2011
220 lung_msk_2017
221 nsclc_mskcc_2018
222 nsclc_pd1_msk_2018
223 nsclc_tracerx_2017
224 nsclc_unito_2016
225 nsclc_mskcc_2015
226 blca_nmibc_2017
227 hnsc_mdanderson_2013
228 ov_tcga
229 ov_tcga_pub
230 ov_tcga_pan_can_atlas_2018
231 nsclc_tcga_broad_2016
232 pancan_pcawg_2020
233 paad_icgc
234 paad_qcmg_uq_2016
235 paad_tcga
236 paad_tcga_pan_can_atlas_2018
237 paad_utsw_2015
238 paad_cptac_2021
239 panet_jhu_2011
240 panet_arcnet_2017
241 thca_tcga_pub
242 all_phase2_target_2018_pub
243 aml_target_2018_pub
244 brain_cptac_2020
245 es_dfarber_broad_2014
246 nbl_target_2018_pub
247 pediatric_dkfz_2017
248 mixed_pipseq_2017
249 pptc_2019
250 rt_target_2018_pub
251 wt_target_2018_pub
252 pcpg_tcga_pub
253 pcpg_tcga
254 pcpg_tcga_pan_can_atlas_2018
255 past_dkfz_heidelberg_2013
256 plmeso_nyu_2015
257 thyroid_mskcc_2016
258 pcnsl_mayo_2015
259 prad_broad_2013
260 prad_broad
261 prad_cpcg_2017
262 prad_fhcrc
263 prad_cdk12_mskcc_2020
264 prad_mskcc
265 prad_mskcc_2014
266 prad_p1000
267 prad_eururol_2017
268 prad_tcga_pub
269 prad_tcga
270 prad_tcga_pan_can_atlas_2018
271 prad_mskcc_cheny1_organoids_2014
272 prostate_dkfz_2018
273 prad_msk_2019
274 prad_mskcc_2017
275 brca_cptac_2020
276 mixed_msk_tcga_2021
277 prad_msk_stopsack_2021
278 rectal_msk_2019
279 hnc_mskcc_2016
280 ccrcc_utokyo_2013
281 nccrcc_genentech_2014
282 rbl_mskcc_2020
283 rbl_cfdna_msk_2020
284 mrt_bcgsc_2016
285 rms_nih_2014
286 summit_2018
287 sarcoma_mskcc_2022
288 sarc_mskcc
289 sarc_tcga
290 sarc_tcga_pan_can_atlas_2018
291 skcm_broad
292 skcm_tcga
293 skcm_tcga_pan_can_atlas_2018
294 skcm_yale
295 skcm_broad_brafresist_2012
296 scco_mskcc
297 sclc_clcgp
298 sclc_jhu
299 sclc_ucologne_2015
300 sclc_cancercell_gardner_2017
301 vsc_cuk_2018
302 stad_pfizer_uhongkong
303 stad_tcga
304 stad_tcga_pub
305 stad_tcga_pan_can_atlas_2018
306 stad_utokyo
307 stad_uhongkong
308 tmb_mskcc_2018
309 tgct_tcga
310 tgct_tcga_pan_can_atlas_2018
311 angs_painter_2020
312 angs_project_painter_2018
313 brca_mbcproject_wagle_2017
314 mpcproject_broad_2021
315 lung_pdx_msk_2021
316 lung_msk_pdx
317 tet_nci_2014
318 thym_tcga
319 thym_tcga_pan_can_atlas_2018
320 thca_tcga
321 thca_tcga_pan_can_atlas_2018
322 ntrk_msk_2019
323 urcc_mskcc_2016
324 utuc_mskcc_2015
325 utuc_cornell_baylor_mdacc_2019
326 utuc_igbmc_2021
327 utuc_msk_2019
328 utuc_pdx_msk_2019
329 blca_cornell_2016
330 ucs_jhu_2014
331 ucs_tcga
332 ucs_tcga_pan_can_atlas_2018
333 uccc_nih_2017
334 ucec_tcga
335 ucec_tcga_pub
336 ucec_tcga_pan_can_atlas_2018
337 usarc_msk_2020
338 um_qimr_2016
339 uvm_tcga
340 uvm_tcga_pan_can_atlas_2018
name
1 Acinar Cell Carcinoma of the Pancreas (JHU, J Pathol 2014)
2 Acral Melanoma (TGEN, Genome Res 2017)
3 Acute Lymphoblastic Leukemia (St Jude, Nat Genet 2015)
4 Acute Lymphoblastic Leukemia (St Jude, Nat Genet 2016)
5 Acute Myeloid Leukemia (OHSU, Nature 2018)
6 Acute Myeloid Leukemia (TCGA, Firehose Legacy)
7 Acute Myeloid Leukemia (TCGA, NEJM 2013)
8 Acute Myeloid Leukemia (TCGA, PanCancer Atlas)
9 Acute myeloid leukemia or myelodysplastic syndromes (WashU, 2016)
10 Adenoid Cystic Carcinoma (FMI, Am J Surg Pathl. 2014)
11 Adenoid Cystic Carcinoma (JHU, Cancer Prev Res 2016)
12 Adenoid Cystic Carcinoma (MDA, Clin Cancer Res 2015)
13 Adenoid Cystic Carcinoma (MGH, Nat Gen 2016)
14 Adenoid Cystic Carcinoma (MSKCC, Nat Genet 2013)
15 Adenoid Cystic Carcinoma (Sanger/MDA, JCI 2013)
16 Adenoid Cystic Carcinoma Project (J Clin Invest 2019)
17 Adenoid Cystic Carcinoma of the Breast (MSKCC, J Pathol. 2015)
18 Adrenocortical Carcinoma (TCGA, Firehose Legacy)
19 Adrenocortical Carcinoma (TCGA, PanCancer Atlas)
20 Adult Soft Tissue Sarcomas (TCGA, Cell 2017)
21 Ampullary Carcinoma (Baylor College of Medicine, Cell Reports 2016)
22 Anaplastic Oligodendroglioma and Anaplastic Oligoastrocytoma (MSKCC, Neuro Oncol 2017)
23 Basal Cell Carcinoma (UNIGE, Nat Genet 2016)
24 Bladder Cancer (MSK/TCGA, 2020)
25 Bladder Cancer (MSKCC, Eur Urol 2014)
26 Bladder Cancer (MSKCC, J Clin Onco 2013)
27 Bladder Cancer (MSKCC, Nat Genet 2016)
28 Bladder Cancer (TCGA, Cell 2017)
29 Bladder Urothelial Carcinoma (BGI, Nat Genet 2013)
30 Bladder Urothelial Carcinoma (DFCI/MSKCC, Cancer Discov 2014)
31 Bladder Urothelial Carcinoma (TCGA, Firehose Legacy)
32 Bladder Urothelial Carcinoma (TCGA, Nature 2014)
33 Bladder Urothelial Carcinoma (TCGA, PanCancer Atlas)
34 Brain Lower Grade Glioma (TCGA, Firehose Legacy)
35 Brain Lower Grade Glioma (TCGA, PanCancer Atlas)
36 Brain Tumor PDXs (Mayo Clinic, 2019)
37 Breast Cancer (HTAN, Cell Rep Med 2022)
38 Breast Cancer (METABRIC, Nature 2012 & Nat Commun 2016)
39 Breast Cancer (MSK, Cancer Cell 2018)
40 Breast Cancer (MSK, Clinical Cancer Res 2020)
41 Breast Cancer (MSK, Nature Cancer 2020)
42 Breast Cancer (MSKCC, NPJ Breast Cancer 2019)
43 Breast Cancer (SMC 2018)
44 Breast Cancer Xenografts (British Columbia, Nature 2015)
45 Breast Fibroepithelial Tumors (Duke-NUS, Nat Genet 2015)
46 Breast Invasive Carcinoma (British Columbia, Nature 2012)
47 Breast Invasive Carcinoma (Broad, Nature 2012)
48 Breast Invasive Carcinoma (Sanger, Nature 2012)
49 Breast Invasive Carcinoma (TCGA, Cell 2015)
50 Breast Invasive Carcinoma (TCGA, Firehose Legacy)
51 Breast Invasive Carcinoma (TCGA, Nature 2012)
52 Breast Invasive Carcinoma (TCGA, PanCancer Atlas)
53 Cancer Cell Line Encyclopedia (Broad, 2019)
54 Cancer Cell Line Encyclopedia (Novartis/Broad, Nature 2012)
55 Cancer Therapy and Clonal Hematopoiesis (MSK, 2021)
56 Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)
57 Cervical Squamous Cell Carcinoma (TCGA, PanCancer Atlas)
58 Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)
59 China Pan-cancer (OrigiMed2020)
60 Cholangiocarcinoma (ICGC, Cancer Discov 2017)
61 Cholangiocarcinoma (MSK, Clin Cancer Res 2018)
62 Cholangiocarcinoma (National Cancer Centre of Singapore, Nat Genet 2013)
63 Cholangiocarcinoma (National University of Singapore, Nat Genet 2012)
64 Cholangiocarcinoma (TCGA, Firehose Legacy)
65 Cholangiocarcinoma (TCGA, PanCancer Atlas)
66 Chronic Lymphocytic Leukemia (Broad, Cell 2013)
67 Chronic Lymphocytic Leukemia (Broad, Nature 2015)
68 Chronic Lymphocytic Leukemia (IUOPA, Nature 2015)
69 Chronic lymphocytic leukemia (ICGC, Nature Genetics 2011)
70 Clear Cell Renal Cell Carcinoma (DFCI, Science 2019)
71 Colon Adenocarcinoma (CaseCCC, PNAS 2015)
72 Colon Cancer (CPTAC-2 Prospective, Cell 2019)
73 Colorectal Adenocarcinoma (DFCI, Cell Reports 2016)
74 Colorectal Adenocarcinoma (Genentech, Nature 2012)
75 Colorectal Adenocarcinoma (TCGA, Firehose Legacy)
76 Colorectal Adenocarcinoma (TCGA, Nature 2012)
77 Colorectal Adenocarcinoma (TCGA, PanCancer Atlas)
78 Colorectal Adenocarcinoma Triplets (MSKCC, Genome Biol 2014)
79 Colorectal Cancer (MSK, 2022)
80 Colorectal Cancer (MSK, Gastroenterology 2020)
81 Combined Hepatocellular and Intrahepatic Cholangiocarcinoma (Peking University, Cancer Cell 2019)
82 Cutaneous Squamous Cell Carcinoma (DFCI, Clin Cancer Res 2015)
83 Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)
84 Cutaneous Squamous Cell Carcinoma (UCSF, NPJ Genom Med 2021)
85 Cutaneous T Cell Lymphoma (Columbia U, Nat Genet 2015)
86 Cystic Tumor of the Pancreas (Johns Hopkins, PNAS 2011)
87 Desmoplastic Melanoma (Broad Institute, Nat Genet 2015)
88 Diffuse Glioma (GLASS Consortium, Nature 2019)
89 Diffuse Large B cell Lymphoma (DFCI, Nat Med 2018)
90 Diffuse Large B-Cell Lymphoma (Broad, PNAS 2012)
91 Diffuse Large B-Cell Lymphoma (Duke, Cell 2017)
92 Diffuse Large B-Cell Lymphoma (TCGA, PanCancer Atlas)
93 Diffuse Large B-cell Lymphoma (BCGSC, Blood 2013)
94 Disparities in metastatic colorectal cancer between Africans and Americans (MSK, 2020)
95 Endometrial Cancer (MSK, 2018)
96 Endometrial Carcinoma (CPTAC, Cell 2020)
97 Esophageal Adenocarcinoma (DFCI, Nat Genet 2013)
98 Esophageal Adenocarcinoma (TCGA, PanCancer Atlas)
99 Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)
100 Esophageal Carcinoma (TCGA, Firehose Legacy)
101 Esophageal Carcinoma (TCGA, Nature 2017)
102 Esophageal Squamous Cell Carcinoma (ICGC, Nature 2014)
103 Esophageal Squamous Cell Carcinoma (UCLA, Nat Genet 2014)
104 Esophageal/Stomach Cancer (MSK, 2020)
105 Ewing Sarcoma (Institut Curie, Cancer Discov 2014)
106 Gallbladder Cancer (MSK, Cancer 2018)
107 Gallbladder Carcinoma (Shanghai, Nat Genet 2014)
108 Gastric Adenocarcinoma (TMUCIH, PNAS 2015)
109 Gastric Cancer (OncoSG, 2018)
110 Germ Cell Tumors (MSKCC, J Clin Oncol 2016)
111 Germ Cell Tumors and Shared Leukemias (MSK, 2020)
112 Glioblastoma (CPTAC, Cell 2021)
113 Glioblastoma (Columbia, Nat Med. 2019)
114 Glioblastoma (TCGA, Cell 2013)
115 Glioblastoma (TCGA, Nature 2008)
116 Glioblastoma Multiforme (TCGA, Firehose Legacy)
117 Glioblastoma Multiforme (TCGA, PanCancer Atlas)
118 Glioma (MSK, Nature 2019)
119 Glioma (MSKCC, Clin Cancer Res 2019)
120 Head and Neck Squamous Cell Carcinoma (Broad, Science 2011)
121 Head and Neck Squamous Cell Carcinoma (Johns Hopkins, Science 2011)
122 Head and Neck Squamous Cell Carcinoma (TCGA, Firehose Legacy)
123 Head and Neck Squamous Cell Carcinoma (TCGA, Nature 2015)
124 Head and Neck Squamous Cell Carcinoma (TCGA, PanCancer Atlas)
125 Hepatocellular Adenoma (INSERM, Cancer Cell 2014)
126 Hepatocellular Carcinoma (MSK, Clin Cancer Res 2018)
127 Hepatocellular Carcinomas (INSERM, Nat Genet 2015)
128 High-Grade Serous Ovarian Cancer (MSK, 2021)
129 Histiocytosis Cobimetinib (MSK, Nature 2019)
130 Hypodiploid Acute Lymphoid Leukemia (St Jude, Nat Genet 2013)
131 Insulinoma (Shanghai, Nat Commun 2013)
132 Intrahepatic Cholangiocarcinoma (JHU, Nat Genet 2013)
133 Intrahepatic Cholangiocarcinoma (MSK, 2020)
134 Intrahepatic Cholangiocarcinoma (MSK, Hepatology 2021)
135 Intrahepatic Cholangiocarcinoma (Mount Sinai 2015)
136 Intrahepatic Cholangiocarcinoma (Shanghai, Nat Commun 2014)
137 Juvenile Papillomatosis and Breast Cancer (MSK, 2020)
138 Kidney Chromophobe (TCGA, Cancer Cell 2014)
139 Kidney Chromophobe (TCGA, Firehose Legacy)
140 Kidney Chromophobe (TCGA, PanCancer Atlas)
141 Kidney Renal Clear Cell Carcinoma (BGI, Nat Genet 2012)
142 Kidney Renal Clear Cell Carcinoma (IRC, Nat Genet 2014)
143 Kidney Renal Clear Cell Carcinoma (TCGA, Firehose Legacy)
144 Kidney Renal Clear Cell Carcinoma (TCGA, Nature 2013)
145 Kidney Renal Clear Cell Carcinoma (TCGA, PanCancer Atlas)
146 Kidney Renal Papillary Cell Carcinoma (TCGA, Firehose Legacy)
147 Kidney Renal Papillary Cell Carcinoma (TCGA, PanCancer Atlas)
148 Liver Hepatocellular Adenoma and Carcinomas (MSK, PLOS One 2018)
149 Liver Hepatocellular Carcinoma (AMC, Hepatology 2014)
150 Liver Hepatocellular Carcinoma (RIKEN, Nat Genet 2012)
151 Liver Hepatocellular Carcinoma (TCGA, Firehose Legacy)
152 Liver Hepatocellular Carcinoma (TCGA, PanCancer Atlas)
153 Low-Grade Gliomas (UCSF, Science 2014)
154 Lung Adenocarcinoma (Broad, Cell 2012)
155 Lung Adenocarcinoma (CPTAC, Cell 2020)
156 Lung Adenocarcinoma (MSKCC, 2020)
157 Lung Adenocarcinoma (MSKCC, 2021)
158 Lung Adenocarcinoma (MSKCC, Science 2015)
159 Lung Adenocarcinoma (NPJ Precision Oncology, MSK 2021)
160 Lung Adenocarcinoma (OncoSG, Nat Genet 2020)
161 Lung Adenocarcinoma (TCGA, Firehose Legacy)
162 Lung Adenocarcinoma (TCGA, Nature 2014)
163 Lung Adenocarcinoma (TCGA, PanCancer Atlas)
164 Lung Adenocarcinoma (TSP, Nature 2008)
165 Lung Cancer (SMC, Cancer Research 2016)
166 Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)
167 Lung Squamous Cell Carcinoma (TCGA, Firehose Legacy)
168 Lung Squamous Cell Carcinoma (TCGA, Nature 2012)
169 Lung Squamous Cell Carcinoma (TCGA, PanCancer Atlas)
170 Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (TCGA, Firehose Legacy)
171 Lymphoma Cell Lines (MSKCC, 2020)
172 MAPK on resistance to anti-HER2 therapy for breast cancer (MSKCC, Nat Comm 2021)
173 MSK MetTropism (MSK, Cell 2021)
174 MSK-IMPACT Clinical Sequencing Cohort (MSKCC, Nat Med 2017)
175 MSK-IMPACT and MSK-ACCESS Mixed Cohort (MSK, 2021)
176 MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)
177 Malignant Peripheral Nerve Sheath Tumor (MSKCC, Nat Genet 2014)
178 Mantle Cell Lymphoma (IDIBIPS, PNAS 2013)
179 Mature B-cell malignancies (MD Anderson Cancer Center)
180 Medulloblastoma (Broad, Nature 2012)
181 Medulloblastoma (DKFZ, Nature 2017)
182 Medulloblastoma (ICGC, Nature 2012)
183 Medulloblastoma (PCGP, Nature 2012)
184 Medulloblastoma (Sickkids, Nature 2016)
185 Melanoma (Broad/Dana Farber, Nature 2012)
186 Melanoma (MSKCC, Clin Cancer Res 2021)
187 Melanoma (MSKCC, NEJM 2014)
188 Melanomas (TCGA, Cell 2015)
189 Merged Cohort of LGG and GBM (TCGA, Cell 2016)
190 Mesothelioma (TCGA, Firehose Legacy)
191 Mesothelioma (TCGA, PanCancer Atlas)
192 Metaplastic Breast Cancer (MSK, 2021)
193 Metastatic Breast Cancer (INSERM, PLoS Med 2016)
194 Metastatic Breast Cancer (MSK, Cancer Discovery 2021)
195 Metastatic Colorectal Cancer (MSKCC, Cancer Cell 2018)
196 Metastatic Esophagogastric Cancer (MSKCC, Cancer Discovery 2017)
197 Metastatic Melanoma (DFCI, Nature Medicine 2019)
198 Metastatic Melanoma (DFCI, Science 2015)
199 Metastatic Melanoma (MSKCC, JCO Precis Oncol 2017)
200 Metastatic Melanoma (UCLA, Cell 2016)
201 Metastatic Prostate Adenocarcinoma (MCTP, Nature 2012)
202 Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019)
203 Metastatic Prostate Cancer (SU2C/PCF Dream Team, Cell 2015)
204 Metastatic Solid Cancers (UMich, Nature 2017)
205 Metastatic castration-sensitive prostate cancer (MSK, Clin Cancer Res 2020)
206 Mixed Tumors (MSK, 2022)
207 Mixed cfDNA (MSK, Nature Medicine 2019)
208 Mixed cfDNA (MSKCC, 2020)
209 Multiple Myeloma (Broad, Cancer Cell 2014)
210 Myelodysplasia (UTokyo, Nature 2011)
211 Myelodysplastic (MSKCC, 2020)
212 Myeloproliferative Neoplasms (CIMR, NEJM 2013)
213 NCI-60 Cell Lines (NCI, Cancer Res 2012)
214 Nasopharyngeal Carcinoma (Singapore, Nat Genet 2014)
215 Neuroblastoma (AMC Amsterdam, Nature 2012)
216 Neuroblastoma (Broad, Nat Genet 2013)
217 Neuroblastoma (Broad, Nature 2015)
218 Neuroendocrine Prostate Cancer (Multi-Institute, Nat Med 2016)
219 Non-Hodgkin Lymphoma (BCGSC, Nature 2011)
220 Non-Small Cell Cancer (MSKCC, Cancer Discov 2017)
221 Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018)
222 Non-Small Cell Lung Cancer (MSKCC, J Clin Oncol 2018)
223 Non-Small Cell Lung Cancer (TRACERx, NEJM & Nature 2017)
224 Non-Small Cell Lung Cancer (University of Turin, Lung Cancer 2017)
225 Non-small cell lung cancer (MSK, Science 2015)
226 Nonmuscle Invasive Bladder Cancer (MSK Eur Urol 2017)
227 Oral Squamous Cell Carcinoma (MD Anderson, Cancer Discov 2013)
228 Ovarian Serous Cystadenocarcinoma (TCGA, Firehose Legacy)
229 Ovarian Serous Cystadenocarcinoma (TCGA, Nature 2011)
230 Ovarian Serous Cystadenocarcinoma (TCGA, PanCancer Atlas)
231 Pan-Lung Cancer (TCGA, Nat Genet 2016)
232 Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020)
233 Pancreatic Adenocarcinoma (ICGC, Nature 2012)
234 Pancreatic Adenocarcinoma (QCMG, Nature 2016)
235 Pancreatic Adenocarcinoma (TCGA, Firehose Legacy)
236 Pancreatic Adenocarcinoma (TCGA, PanCancer Atlas)
237 Pancreatic Cancer (UTSW, Nat Commun 2015)
238 Pancreatic Ductal Adenocarcinoma (CPTAC, Cell 2021)
239 Pancreatic Neuroendocrine Tumors (Johns Hopkins University, Science 2011)
240 Pancreatic Neuroendocrine Tumors (Multi-Institute, Nature 2017)
241 Papillary Thyroid Carcinoma (TCGA, Cell 2014)
242 Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)
243 Pediatric Acute Myeloid Leukemia (TARGET, 2018)
244 Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)
245 Pediatric Ewing Sarcoma (DFCI, Cancer Discov 2014)
246 Pediatric Neuroblastoma (TARGET, 2018)
247 Pediatric Pan-Cancer (DKFZ, Nature 2017)
248 Pediatric Pan-cancer (Columbia U, Genome Med 2016)
249 Pediatric Preclinical Testing Consortium (CHOP, Cell Rep 2019)
250 Pediatric Rhabdoid Tumor (TARGET, 2018)
251 Pediatric Wilms' Tumor (TARGET, 2018)
252 Pheochromocytoma and Paraganglioma (TCGA, Cell 2017)
253 Pheochromocytoma and Paraganglioma (TCGA, Firehose Legacy)
254 Pheochromocytoma and Paraganglioma (TCGA, PanCancer Atlas)
255 Pilocytic Astrocytoma (ICGC, Nature Genetics 2013)
256 Pleural Mesothelioma (NYU, Cancer Res 2015)
257 Poorly-Differentiated and Anaplastic Thyroid Cancers (MSKCC, JCI 2016)
258 Primary Central Nervous System Lymphoma (Mayo Clinic, Clin Cancer Res 2015)
259 Prostate Adenocarcinoma (Broad/Cornell, Cell 2013)
260 Prostate Adenocarcinoma (Broad/Cornell, Nat Genet 2012)
261 Prostate Adenocarcinoma (CPC-GENE, Nature 2017)
262 Prostate Adenocarcinoma (Fred Hutchinson CRC, Nat Med 2016)
263 Prostate Adenocarcinoma (MSK, Eur Urol 2020)
264 Prostate Adenocarcinoma (MSKCC, Cancer Cell 2010)
265 Prostate Adenocarcinoma (MSKCC, PNAS 2014)
266 Prostate Adenocarcinoma (MSKCC/DFCI, Nature Genetics 2018)
267 Prostate Adenocarcinoma (SMMU, Eur Urol 2017)
268 Prostate Adenocarcinoma (TCGA, Cell 2015)
269 Prostate Adenocarcinoma (TCGA, Firehose Legacy)
270 Prostate Adenocarcinoma (TCGA, PanCancer Atlas)
271 Prostate Adenocarcinoma Organoids (MSKCC, Cell 2014)
272 Prostate Cancer (DKFZ, Cancer Cell 2018)
273 Prostate Cancer (MSK, Cell Metab 2020)
274 Prostate Cancer (MSKCC, JCO Precis Oncol 2017)
275 Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)
276 RAD51B Associated Mixed Cancers (Mandelker 2021)
277 Race Differences in Prostate Cancer (MSK, 2021)
278 Rectal Cancer (MSK,Nature Medicine 2019)
279 Recurrent and Metastatic Head & Neck Cancer (MSKCC, JAMA Oncol 2016)
280 Renal Clear Cell Carcinoma (UTokyo, Nat Genet 2013)
281 Renal Non-Clear Cell Carcinoma (Genentech, Nat Genet 2014)
282 Retinoblastoma (MSK, Cancers 2021)
283 Retinoblastoma cfDNA (MSKCC 2020)
284 Rhabdoid Cancer (BCGSC, Cancer Cell 2016)
285 Rhabdomyosarcoma (NIH, Cancer Discov 2014)
286 SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018)
287 Sarcoma (MSK, 2022)
288 Sarcoma (MSKCC/Broad, Nat Genet 2010)
289 Sarcoma (TCGA, Firehose Legacy)
290 Sarcoma (TCGA, PanCancer Atlas)
291 Skin Cutaneous Melanoma (Broad, Cell 2012)
292 Skin Cutaneous Melanoma (TCGA, Firehose Legacy)
293 Skin Cutaneous Melanoma (TCGA, PanCancer Atlas)
294 Skin Cutaneous Melanoma (Yale, Nat Genet 2012)
295 Skin Cutaneous Melanoma(Broad, Cancer Discov 2014)
296 Small Cell Carcinoma of the Ovary (MSKCC, Nat Genet 2014)
297 Small Cell Lung Cancer (CLCGP, Nat Genet 2012)
298 Small Cell Lung Cancer (Johns Hopkins, Nat Genet 2012)
299 Small Cell Lung Cancer (U Cologne, Nature 2015)
300 Small-Cell Lung Cancer (Multi-Institute, Cancer Cell 2017)
301 Squamous Cell Carcinoma of the Vulva (CUK, Exp Mol Med 2018)
302 Stomach Adenocarcinoma (Pfizer and UHK, Nat Genet 2014)
303 Stomach Adenocarcinoma (TCGA, Firehose Legacy)
304 Stomach Adenocarcinoma (TCGA, Nature 2014)
305 Stomach Adenocarcinoma (TCGA, PanCancer Atlas)
306 Stomach Adenocarcinoma (U Tokyo, Nat Genet 2014)
307 Stomach Adenocarcinoma (UHK, Nat Genet 2011)
308 TMB and Immunotherapy (MSKCC, Nat Genet 2019)
309 Testicular Germ Cell Cancer (TCGA, Firehose Legacy)
310 Testicular Germ Cell Tumors (TCGA, PanCancer Atlas)
311 The Angiosarcoma Project (Provisional, July 2020)
312 The Angiosarcoma Project - Count Me In (Nature Medicine, 2020)
313 The Metastatic Breast Cancer Project (Provisional, February 2020)
314 The Metastatic Prostate Cancer Project (Provisional, June 2021)
315 Thoracic Cancer (MSK, 2021)
316 Thoracic PDX (MSK, Provisional)
317 Thymic Epithelial Tumors (NCI, Nat Genet 2014)
318 Thymoma (TCGA, Firehose Legacy)
319 Thymoma (TCGA, PanCancer Atlas)
320 Thyroid Carcinoma (TCGA, Firehose Legacy)
321 Thyroid Carcinoma (TCGA, PanCancer Atlas)
322 Tumors with TRK fusions (MSK, Clin Cancer Res 2020)
323 Unclassified Renal Cell Carcinoma (MSK, Nature 2016)
324 Upper Tract Urothelial Cancer (MSK, Eur Urol 2015)
325 Upper Tract Urothelial Carcinoma (Cornell/Baylor/MDACC, Nat Commun 2019)
326 Upper Tract Urothelial Carcinoma (IGBMC, Genome Biology 2021)
327 Upper Tract Urothelial Carcinoma (MSK, Nat Commun 2020)
328 Upper Tract Urothelial Carcinoma PDX (MSK, Nat Commun 2020)
329 Urothelial Carcinoma (Cornell/Trento, Nat Gen 2016)
330 Uterine Carcinosarcoma (Johns Hopkins, Nat Commun 2014)
331 Uterine Carcinosarcoma (TCGA, Firehose Legacy)
332 Uterine Carcinosarcoma (TCGA, PanCancer Atlas)
333 Uterine Clear Cell Carcinoma (NIH, Cancer 2017)
334 Uterine Corpus Endometrial Carcinoma (TCGA, Firehose Legacy)
335 Uterine Corpus Endometrial Carcinoma (TCGA, Nature 2013)
336 Uterine Corpus Endometrial Carcinoma (TCGA, PanCancer Atlas)
337 Uterine Sarcoma/Mesenchymal (MSK, Clin Cancer Res 2020)
338 Uveal Melanoma (QIMR, Oncotarget 2016)
339 Uveal Melanoma (TCGA, Firehose Legacy)
340 Uveal Melanoma (TCGA, PanCancer Atlas)
description
1 Whole exome sequencing of 23 surgically resected pancreatic carcinomas with acinar differentiation and their matched normals.
2 Whole exome sequencing and transcriptome analysis of 34 Acral Melanoma patients (33 with matched normals).
3 Comprehensive profiling of infant MLL-rearranged acute lymphoblastic leukemia (MLL-R ALL)
4 Whole-genome and/or whole-exome sequencing of ERG-altered B-ALL tumor/normal pairs.
5 Whole-exome sequencing of 672 acute myeloid leukemia samples (with 454 matched normals) from the Beat AML program.
6 TCGA Acute Myeloid Leukemia. Source data from GDAC Firehose. Previously known as TCGA Provisional.
7 Whole-genome or whole-exome sequencing analysis of 200 adult de novo AML tumor/normal pairs. TCGA Acute Myeloid Leukemia Project; raw data at the NCI.
8 Acute Myeloid Leukemia TCGA PanCancer data. The original data is here. The publications are here.
9 Enhanced exome or targeted sequencing of 116 acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) patients' tumor/normal pairs .
10 Targeted Sequencing of 28 metastatic Adenoid Cystic Carcinoma samples.
11 Whole-genome or whole-exome sequencing of 25 adenoid cystic carcinoma tumor/normal pairs.
12 WGS of 21 salivary ACCs and targeted molecular analyses of a validation set (81 patients).
13 Whole-genome/exome sequencing of 10 ACC PDX models.
14 Whole-exome or whole-genome sequencing analysis of 60 ACC tumor/normal pairs
15 Whole exome sequencing of 24 ACCs.
16 Multi-Institute Cohort of 1045 Adenoid Cystic Carcinoma patients.
17 Whole exome sequencing of 12 breast AdCCs.
18 TCGA Adrenocortical Carcinoma. Source data from GDAC Firehose. Previously known as TCGA Provisional.
19 Adrenocortical Carcinoma TCGA PanCancer data. The original data is here. The publications are here.
20 Whole-exome sequencing of 206 Adult Soft Tissue Sarcoma tumor/normal pairs.
21 Exome sequencing analysis of 160 cancers arising in the periampullary region, 62 of these clearly arising from either the bile duct (n = 44) or the duodenum (n = 18) and 98 for which the epithelium of origin could not be clearly defined morphologically (AMPCA).
22 IMPACT sequencing of 22 Anaplastic Oligodendroglioma and Anaplastic Oligoastrocytomas.
23 Whole-exome sequencing of 126 basal cell carcinoma tumor/normal pairs; targeted sequencing of 163 sporadic samples (40 tumor/normal pairs) and 4 Gorlin symdrome basal cell carcinomas.
24 Whole-exome or targeted sequencing of 476 muscle-invasive bladder tumor/normal pairs via TCGA or MSK-IMPACT sequencing.
25 Genomic Predictors of Survival in Patients with High-grade Urothelial Carcinoma of the Bladder. Targeted sequencing of 109 tumor samples (MSKCC, European Urology 2014).
26 Comprehensive profiling of 97 high-grade bladder tumors, including targeted sequencing of 15 cancer genes
27 Whole exome and targeted sequencing of 34 plasmacytoid-variant (signet ring cell) tumors of the bladder
28 Whole-exome sequencing of 412 muscle-invasive bladder tumors and matched normal samples.
29 Whole-exome and whole-genome sequencing of 99 bladder cancer tumor/normal pairs. Generated by BGI.
30 Whole exome sequencing of tumor/normal samples from 50 patients treated with cisplatin-based chemotherapy for muscle invasive urothelial carcinoma.
31 TCGA Bladder Urothelial Carcinoma. Source data from GDAC Firehose. Previously known as TCGA Provisional.
32 Whole-exome sequencing of 131 high-grade muscle-invasive urothelial bladder carcinomas
33 Bladder Urothelial Carcinoma TCGA PanCancer data. The original data is here. The publications are here.
34 TCGA Brain Lower Grade Glioma. Source data from GDAC Firehose. Previously known as TCGA Provisional.
35 Brain Lower Grade Glioma TCGA PanCancer data. The original data is here. The publications are here.
36 WES on a total of 83 PDXs and 55 PDXs have the matched germline (blood) samples sequenced. A total of 66 PDXs have RNASeq available
37 Sequencing data from breast cancer patient from HTAN
38 Targeted sequencing of 2509 primary breast tumors with 548 matched normals.
39 Targeted Sequencing of tumor/normal sample pairs from 1918 Breast cancers.
40 Whole-exome and MSK-IMPACT sequencing of 60 tumor/normal matched samples.
41 Targeted sequencing of pre- and post-treatment tumor/cfDNA samples from 51 Breast Cancer patients to understand the mechanisms of resistance to Alepelisib.
42 Targeted Sequencing of buparlisib + letrozole and alpelisib + letrozole-treated metastatic ER+ unmatched breast tumors.
43 Whole-exome sequencing of 187 primary tumors from a Korean breast cancer cohort (SMC).
44 Whole genome/targeted sequencing to evaluate the clonal dynamics in 116 breast cancer patient xenografts.
45 Whole exome sequencing of 22 phyllodes tumors
46 Whole genome/exome sequencing analysis of 65 breast cancer samples
47 Whole-exome sequencing of 103 breast cancer tumor/normal sample pairs. Generated by the Broad Institute.
48 Whole exome sequencing from 100 breast cancer tumor/normal sample pairs. Generated by the Sanger Institute.
49 Whole-exome sequencing of 817 Breast Invasive Carcinoma tumor/normal pairs. The Cancer Genome Atlas (TCGA) Breast Invasive Carcinoma Project.
50 TCGA Breast Invasive Carcinoma. Source data from GDAC Firehose. Previously known as TCGA Provisional.
51 Whole-exome sequencing (510 samples with matched normals), genomic DNA copy number arrays, DNA methylation, messenger RNA arrays, microRNA sequencing and reverse-phase protein arrays analysis on 825 primary breast cancer samples. The Cancer Genome Atlas (TCGA) Breast Invasive Carcinoma project. 825 cases.
Nature 2012. Raw data via the TCGA Data Portal.
52 Breast Invasive Carcinoma TCGA PanCancer data. The original data is here. The publications are here.
53 Cancer Cell Line Encyclopedia from the Broad Institute and Novartis, updated 2019. Data downloaded from the Broad CCLE Portal. For more info about the proteomics data, see the README.
54 Targeted sequencing of 1020 samples from Cancer Cell Line Encyclopedia from the Broad Institute and Novartis.
55 Clonal hematopoiesis mutations identified in blood samples from patients whose tumor-blood pairs were analyzed using MSK-IMPACT.
56 Clonal hematopoiesis mutations identified in blood samples from 24,146 patients whose tumor-blood pairs were analyzed using MSK-IMPACT.
57 Cervical Squamous Cell Carcinoma TCGA PanCancer data. The original data is here. The publications are here.
58 TCGA Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma. Source data from GDAC Firehose. Previously known as TCGA Provisional.
59 Landscape of genomic alterations in 10,194 solid tumors from the Chinese population
60 Whole-exome sequencing and Targeted/Exome sequencing of 489 Cholangiocarcinoma samples from 10 countries.
61 Targeted sequencing (MSK-IMPACT) of 195 tumor samples (194 with matched normals) from 192 cholangiocarcinoma patients.
62 Exome sequencing of 15 cholangiocarcinoma cases.
63 Exome Sequencing for Opisthorchis viverrini-related cholangiocarcinoma in 8 O.viverrini-related tumors and matched normal tissue.
64 TCGA Cholangiocarcinoma. Source data from GDAC Firehose. Previously known as TCGA Provisional.
65 Cholangiocarcinoma TCGA PanCancer data. The original data is here. The publications are here.
66 Whole-exome sequencing of 160 CLL tumor/normal pairs.
67 Whole exome sequencing of 537 chronic lymphocytic leukemia tumor/normal pairs.
68 Mutation data from whole-genome or whole-exome sequencing of 428 CLL, 54 MBL, and 24 SLL tumor/normal pairs.
69 Whole-exome sequencing of 105 Chronic Lymphocytic Leukemia samples.
70 Whole-exome sequencing of metastatic clear cell renal carcinoma (ccRCC) from 35 tumor/normal pairs.
71 Whole-exome sequencing of tumor/normal pairs from 29 African American Colon Cancers.
72 Proteogenomic analysis of prospectively collected 110 human colon adenocarcinoma tumor normal pairs. Data generated by CPTAC.
73 Whole-exome sequencing of 619 colorectal cancers with clinicopathologic annotations.
74 Whole-genome sequencing of 74 paired colon tumor-normal samples.
75 TCGA Colorectal Adenocarcinoma. Source data from GDAC Firehose. Previously known as TCGA Provisional.
76 Whole exome sequencing in 224 of the 276 colorectal carcinoma tumor/normal pairs. The Cancer Genome Atlas (TCGA) Colorectal Cancer project.
77 Colorectal Adenocarcinoma TCGA PanCancer data. The original data is here. The publications are here.
78 Targeted sequencing of primary, metastatic, and normal tissues from 69 colorectal adenocarcinoma patients.
79 Molecular characterization of 47 BRAF inhibitor-naive colorectal cancer patients with dual RAS hotspot/BRAF V600E mutations.
80 Targeted sequencing of 471 unresectable colorectal tumor/normal pairs via MSK-IMPACT.
81 Whole-exome sequencing of 121 combined hepatocellular and intrahepatic cholangiocarcinoma (cHCC-ICC) patients with matched normal pairs (whole-genome sequenced samples are not included here).
82 Targeted sequencing of 29 metastatic cutaneous squamous cell carcinoma samples.
83 Whole-exome sequencing of tumor/normal pairs from 39 aggressive cutaneous squamous cell carcinoma cases.
84 Catalogue of driver genes in cutaneous squamous cell carcinoma. Meta-analysis of 105 normal/tumor pairs.
85 Whole-Exome Sequencing (WXS) of tumor-normal sample pairs from 25 patients with Sezary Syndrome and 17 patients with other Cutaneous T Cell Lymphoma (CTCLs).
86 Whole-exome sequencing of major neoplastic cyst types of the pancreas: 8 serous cystadenomas (SCAs), 8 intraductal papillary mucinous neoplasms (IPMNs), 8 mucinous cystic neoplasms (MCNs), and 8 solid pseudopapillary neoplasms (SPNs).
87 Exome/Whole Genome sequencing of 20 desmoplastic melanoma tumor/normal pairs.
88 Whole genome or whole exome sequencing analysis of temporally separated diffuse glioma tumor/normal pairs from 222 adult patients.
89 Whole-exome sequencing of tumor/matching normal sample pairs from 135 DLBCL patients.
90 Whole exome sequencing of 58 primary DLBCL samples and their matched normals.
91 Whole-exome sequencing of 1,001 Diffuse Large B Cell Lymphoma (DLBCL) tumors (N = 1001) and paired-normal tissue (N = 400).
92 Diffuse Large B-Cell Lymphoma TCGA PanCancer data. The original data is here. The publications are here.
93 Whole genome sequencing of 40 DLBCL tumor/normal pairs and 13 cell lines.
94 Targeted sequencing of 64 colorectal tumor/normal pairs via MSK-IMPACT to determine the epigenetic differences seen in Nigerian patients.
95 MSK-IMPACT sequencing of 197 advanced-staged endometrial cancer tumor samples with matched normals, from 189 patients treated at MSK.
96 Proteogenomic Characterization of Endometrial Carcinoma. Generated by CPTAC.
97 Whole-exome sequencing of 149 tumor/normal pairs and whole-genome sequencing of 16 pairs from 149 esophageal adenocarcinoma patients.
98 Esophageal Adenocarcinoma TCGA PanCancer data. The original data is here. The publications are here.
99 Targeted and WES recapture sequencing of tumor/normal samples from 37 Esophageal Cancer patients.
100 TCGA Esophageal Carcinoma . Source data from GDAC Firehose. Previously known as TCGA Provisional.
101 Whole exome sequencing of 559 esophageal and gastric carcinoma tumors with matched normals.
102 Whole-genome or whole-exome sequencing of 88 esophageal squamous cell carcinoma tumor/normal pairs.
103 Whole exome sequencing (WXS) or targeted deep sequencing (TDS) of 139 paired esophageal squamous cell carcinoma patients.
104 Targeted sequencing of 487 Esophageal/stomach cancer tumor-normal pairs via MSK-IMPACT.
105 Whole-genome sequencing of 112 Ewing sarcoma samples and matched germ line DNA.
106 Targeted Sequencing of 103 samples with matched normals from 101 Gallbladder cancer patients.
107 Whole exome sequencing of 32 gallbladder carcinoma tumor/normal pairs.
108 Whole-exome sequencing of 78 Gastric Adenocarcinomas and their matched normal samples.
109 Whole-genome sequencing of 147 gastric cancer tumors with matched normals. Courtesy of OncoSG.
110 Whole-exome and Targeted sequencing of 19 samples and Targeted sequencing of 161 samples from 180 Germ Cell Tumor patients.
111 Targeted and WES sequencing of germ cell tumor and shared leukemia samples.
112 Proteogenomic and metabolomic characterization of human glioblastoma. Whole genome or whole exome sequencing of 99 samples. Generated by CPTAC.
113 Whole-exome sequencing of 32 out of 42 glioblastomas patients with matched normals.
114 Whole-exome and/or whole-genome sequencing of 291 of the 577 glioblastoma tumor/normal pairs. The Cancer Genome Atlas (TCGA) Glioblastoma Project.
115 Targeted sequencing in 91 of the 206 primary glioblastoma tumors (143 with matched normals) from the Cancer Genome Atlas (TCGA) Glioblastoma Project.
116 TCGA Glioblastoma Multiforme. Source data from GDAC Firehose. Previously known as TCGA Provisional.
117 Glioblastoma Multiforme TCGA PanCancer data. The original data is here. The publications are here.
118 Targeted Sequencing of CSF samples (91 samples with 86 matched normals) from 42 glioma patients.
119 Targeted sequencing on MSK-IMPACT and FMI Panels of 1004 samples (837 with matched normals) from 923 glioma patients.
120 Whole-exome sequencing of 74 head and neck squamous cell carcinoma tumor/normal pairs.
121 Exome sequencing of 32 head and neck squamous cell carcinoma tumor/normal sample pairs.
122 TCGA Head and Neck Squamous Cell Carcinoma. Source data from GDAC Firehose. Previously known as TCGA Provisional.
123 Whole-exome sequencing and/or whole-genome sequencing of 279 head and neck squamous cell carcinoma tumor/normal pairs. The Cancer Genome Atlas (TCGA) head and neck squamous cell carcinoma Project.
124 Head and Neck Squamous Cell Carcinoma TCGA PanCancer data. The original data is here. The publications are here.
125 Whole-exome sequencing of 46 liver tumor/normal pairs.
126 MSK-IMPACT sequencing of 127 Hepatocellular Carcinoma tumor samples with matched normals.
127 Whole-exome sequencing of 243 liver tumors and matched normals.
128 Targeted Sequencing of 45 Serous Ovarian Cancer tumor/normal pairs from 45 patients.
129 Targeted and whole exome sequencing of 52 histiocytosis tumor/normal pairs.
130 Whole genome or exome sequencing of 44 (20 whole genome, 20 exome) ALL tumor/normal pairs.
131 Whole exome sequencing of 10 benign insulinoma tumor/normal pairs.
132 Exome sequencing of tumor/normal pairs from 32 intrahepatic cholangiocarcinoma cases and 8 gall bladder carcinoma cases.
133 Targeted sequencing of IMPACT and CMO samples
134 Targeted sequencing of 412 intrahepatic cholangiocarcinoma tumor/normal sample pairs.
135 Whole-exome sequencing of 8 tumor-normal paired iCCA samples by Liver Cancer Program at the Icahn School of Medicine at Mount Sinai, in collaboration with Barcelona-ClÃnic Liver Cancer Group.
136 Whole exome sequencing of 103 tumor/normal sample pairs in 103 intrahepatic cholangiocarcinoma patients.
137 Whole-exome sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma.
138 Whole-exome sequencing of 66 chromophobe renal cell carcinoma (ChRCCs) tumor/normal pairs.
139 TCGA Kidney Chromophobe. Source data from GDAC Firehose. Previously known as TCGA Provisional.
140 Kidney Chromophobe TCGA PanCancer data. The original data is here. The publications are here.
141 Whole-exome sequencing of 10 ccRCC tumor/normal pairs and targeted sequencing of 88 clear cell carcinoma tumor/normal pairs. Generated by BGI-Shenzhen.
142 Multi region exome sequencing of 10 clear cell renal cell carcinomas (ccRCCs)
143 TCGA Kidney Renal Clear Cell Carcinoma. Source data from GDAC Firehose. Previously known as TCGA Provisional.
144 Whole-exome sequencing in 417 of 446 clear cell renal cell carcinoma tumor/normal pairs.
145 Kidney Renal Clear Cell Carcinoma TCGA PanCancer data. The original data is here. The publications are here.
146 TCGA Kidney Renal Papillary Cell Carcinoma. Source data from GDAC Firehose. Previously known as TCGA Provisional.
147 Kidney Renal Papillary Cell Carcinoma TCGA PanCancer data. The original data is here. The publications are here.
148 Targeted sequencing of tumor/normal pairs of 9 LIAD and 10 HCC patients via MSK-IMPACT platform.
149 Whole exome sequencing of 231 hepatocellular carcinomas and matched normal tissue pairs.
150 Whole-genome sequencing of 27 hepatocellular carcinoma tumor/norma pairs from RIKEN.
151 TCGA Liver Hepatocellular Carcinoma. Source data from GDAC Firehose. Previously known as TCGA Provisional.
152 Liver Hepatocellular Carcinoma TCGA PanCancer data. The original data is here. The publications are here.
153 Whole exome sequencing of 23 grade II glioma tumor/normal pairs.
154 Whole-exome and/or whole-genome sequencing of 183 lung adenocarcinomas and matched normal tissue pairs.
155 Whole genome (WGS) or whole exome sequencing (WES) of 110 tumors and 101 matched normal adjacent tissues in lung adenocarcinoma. Proteogenomic characterization generated by CPTAC.
156 Targeted sequencing of 604 lung adenocarcinoma tumor/normal pairs via MSK-IMPACT.
157 Targeted sequencing of 186 matched normal samples from 186 lung adenocarcinoma patient via MSK-IMPACT.
158 Whole-exome sequencing of 34 non small cell lung cancer tumor/normal pairs.
159 Targeted sequencing of 426 matched normal samples from 426 lung adenocarcinoma patients.
160 Whole-exome and transcriptome sequencing of 305 east asian lung adenocarcinomas with matched normals. Courtesy of OncoSG. Lung Cancer Consortium Singapore (LCCS).
161 TCGA Lung Adenocarcinoma. Source data from GDAC Firehose. Previously known as TCGA Provisional.
162 Whole exome sequencing of 230 lung adenocarcinoma tumor/normal pairs. Raw data via the TCGA Data Portal.
163 Lung Adenocarcinoma TCGA PanCancer data. The original data is here. The publications are here.
164 Targeted sequencing of 163 lung adenocarcinoma tumor/normal pairs. Generated by WashU/Broad.
165 Whole exome and whole transcriptome sequencing of primary and multiple metastatic lymph node samples from 6 lung cancer patients with their matched normals.
166 Whole genome / whole exome sequencing and proteogenomic portrait of 108 prospectively collected, treatment-naive, primary LSCC tumors and 99 paired normal adjacent tissues. Generated by CPTAC.
167 TCGA Lung Squamous Cell Carcinoma. Source data from GDAC Firehose. Previously known as TCGA Provisional.
168 Whole exome sequencing of 178 lung squamous cell carcinoma tumor/normal pairs. The Cancer Genome Atlas (TCGA) Lung Squamous Cell Carcinoma project.
169 Lung Squamous Cell Carcinoma TCGA PanCancer data. The original data is here. The publications are here.
170 TCGA Lymphoid Neoplasm Diffuse Large B-cell Lymphoma. Source data from GDAC Firehose. Previously known as TCGA Provisional.
171 Targeted sequencing of 34 lymphoma cell lines using HemePACT_v3
172 MSK-IMPACT targeted sequencing of 145 breast tumors with matched normal samples.
173 MSK-MET (Memorial Sloan Kettering - Metastatic Events and Tropisms) is an integrated pan-cancer cohort of tumor genomic and clinical outcome data from 25,000 patients. We analyzed this dataset to identify associations between tumor genomic alterations and patterns of metastatic dissemination across 50 tumor types. We found that chromosomal instability is strongly correlated with metastatic burden in some tumor types, including prostate adenocarcinoma, lung adenocarcinoma and HR+/HER2+ breast ductal carcinoma, but not in others, such as colorectal MSS, pancreatic adenocarcinoma and high-grade serous ovarian cancer. We also identified specific somatic alterations associated with increased metastatic burden and specific routes of metastatic spread. Our data offer a unique resource for the investigation of the biologic basis for metastatic spread and highlight the crucial role of chromosomal instability in cancer progression. PubMed
174 Targeted sequencing of 10,000 clinical cases using the MSK-IMPACT assay
175 Targeted sequencing of 1446 Tumor and cfDNA samples (1440 with matched normals) from MSK-IMPACT and MSK-ACCESS.
176 Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.
177 Whole exome sequencing of 15 malignant peripheral nerve sheath tumor/normal pairs.
178 Whole exome sequencing of 29 primary mantle cell lymphomas and their matched normals.
179 We performed targeted deep sequencing of 380 recurrently mutated genes across a cohort of 755 mature B-cell malignancies to define conserved and disease-specific patterns of genomic alterations.PubMed
180 Whole exome sequencing of 92 primary medulloblastoma tumor/normal pairs.
181 Whole genome or whole exome sequencing of 491 previously untreated Medulloblastoma tumor/normal pairs.
182 Comprehensive profiling of 125 matched tumor and germline medulloblastoma samples
183 Whole genome sequencing of 37 medulloblastoma tumors and their matched normals from the Pediatric Cancer Genome Project (PCGP), a joint project by St. Jude Children's Research Hospital and Washington University.
184 Whole-genome sequencing of 46 recurrent medulloblastoma samples.
185 Whole Genome Sequencing of 25 metastatic melanoma samples with matched normals
186 Targeted sequencing (MSK-IMPACT) of 696 melanoma tumor/normal pairs.
187 Whole-exome sequencing of 64 pretreated (ipilimumab or tremelimumab) melanoma tumor-normal pairs.
188 Whole-exome sequencing of 333 primary and/or metastatic melanomas.
189 Whole exome sequencing of 1,122 LGG and GBM tumor/normal pairs.
190 TCGA Mesothelioma. Source data from GDAC Firehose. Previously known as TCGA Provisional.
191 Mesothelioma TCGA PanCancer data. The original data is here. The publications are here.
192 Targeted or whole-exome sequencing of 19 Metaplastic Breast Cancer tumor/normal pairs.
193 Whole exome sequencing of 216 tumor/normal (blood) pairs from metastatic breast cancer patients who underwent a biopsy in the context of the SAFIR01/SAFIR02 (Unicancer, France), SHIVA (Institut Curie, France) or MOSCATO (Gustave Roussy, France) prospective trials.
194 Targeted Sequencing of 1365 metastatic Breast Cancer tumor/normal pairs via MSK-IMPACT to understand the role of INK4 on CDK4/6 resistance.
195 Targeted sequencing of 1134 metastatic colorectal tumor/normal pairs.
196 Targeted sequencing of 341 samples from 305 metastatic esophagogastric cancer patients
197 Whole-exome sequencing of 144 pre-treatment samples from 144 patients with metastatic melanoma treated with anti-PD1 ICB.
198 Whole-exome sequencing of 110 metastatic melanoma tumor-normal pairs.
199 Targeted sequencing of pre-treatment 66 Melanoma tumor samples. PubMed
200 Whole-exome sequencing of 38 pretreated (pembrolizumab, nivolumab) melanoma tumor-normal pairs.
201 Exome sequencing of 61 prostate cancer tumor/normal pairs (50 metastatic CRPCs and 11 high-grade localized prostate cancers). Generated by Arul Chinnaiyan's and Scott Tomlins' labs at the University of Michigan.
202 Whole exome sequencing of 444 castrate resistant prostate cancer tumor/normal pairs. SU2C-PCF Dream Team: Precision Therapy for Advanced Prostate Cancer.
203 Whole-exome sequencing of 150 metastatic prostate cancer tumor/normal pairs by the SU2C/PCF Dream Team.
204 Whole-exome and -transcriptome sequencing of 500 adult patients with metastatic solid tumor/primary normal pairs of diverse lineage and biopsy site.
205 MSK-IMPACT sequencing of 424 matched tumor-normal samples from patients with metastatic castration-sensitive prostate cancer. Germline alterations are not shown here.
206 Targeted NGS of mixed tumors from MSK-IMPACT testing.
207 Targeted sequencing of 248 samples from 124 patients' cfDNA/WBC and tumor/normal pairs.
208 IMPACT sequencing of 229 cell-free DNA (cfDNA) and associated tumor samples with matched normal
209 Whole-exome or whole-genome sequencing of 203 multiple myeloma paired tumor/normal sample pairs.
210 Whole exome sequencing of 29 myelodysplasia tumor/normal pairs.
211 Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms
212 Whole exome sequencing of paired tumor/normal pairs from 151 cases of Myeloproliferative Neoplasms.
213 Whole-exome sequencing of 67 samples by NCI-60 cell line project; raw data at CellMiner.
214 Whole exome sequencing of 56 NPC tumor/normal pairs.
215 Whole genome sequencing of 87 primary neuroblastoma tumors and their matched normals.
216 Whole Genome and Whole Exome sequencing of 240 high-risk neuroblastoma tumor/normal pairs.
217 Whole-genome sequencing of 56 neuroblastoma tumor/normal pairs.
218 Whole exome sequencing of 114 metastatic tumor/normal pairs to understand genomic overlap between castration resistant adenocarcinoma (CRPC-Adeno) and neuroendocrine histologies (CRPC-NE).
219 Whole genome or whole exome sequencing of 14 NHL tumors and their matched normals.
220 Targeted sequencing of 860 patients with metastatic lung adenocarcinoma
221 Whole-exome sequencing of 75 tumor/normal NSCLC pairs treated with PD-1 plus CTLA-4 blockade..
222 IMPACT sequencing of 240 NSCLC tumor/normal pairs treated at MSKCC with anti-PD-(L)1 based therapy.
223 Whole-exome sequencing of 327 primary tumors with matched germline samples, and phylogenetic ctDNA sequencing of 96 pre- and 24 postoperative samples from 100 NSCLC TRACERx patients.
224 Targeted next-generation sequencing of 41 NSCLC samples.
225 Whole-exome sequencing of tumor-normal tissue pairs from 16 non-small cell lung cancer samples.
226 IMPACT sequencing of 105 High Risk Nonmuscle Invasive Bladder Cancer samples.
227 Whole-exome sequencing of 40 oral squamous cell carcinoma tumor/normal sample pairs.
228 TCGA Ovarian Serous Cystadenocarcinoma. Source data from GDAC Firehose. Previously known as TCGA Provisional.
229 Whole exome sequencing of 489 high-grade serous ovarian adenocarcinoma tumor/normal pairs. The Cancer Genome Atlas (TCGA) Serous Ovarian Cancer project. 489 cases.
Raw data via the TCGA Data Portal.
230 Ovarian Serous Cystadenocarcinoma TCGA PanCancer data. The original data is here. The publications are here.
231 Whole-exome sequencing of 660 lung ADC and 484 lung SqCC tumor/normal pairs.
232 WGS changes cataloged in 2,583 whole-cancer genomes and their matched normal tissues across 38 tumor types. Source data from UCSC Xena and ICGC Data Portal.
233 Whole-exome sequencing of 99 pancreatic samples and their matched normals.
234 Whole-genome and deep-exome sequencing analysis of 456 pancreatic ductal adenocarcinomas
235 TCGA Pancreatic Adenocarcinoma. Source data from GDAC Firehose. Previously known as TCGA Provisional.
236 Pancreatic Adenocarcinoma TCGA PanCancer data. The original data is here. The publications are here.
237 Whole exome sequencing of 109 micro-dissected pancreatic cancer cases and normal control tissue.
238 Whole-genome sequencing (WGS) and whole-exome sequencing (WES) of 140 pancreatic cancers with 67 normal adjacent tissues. Proteogenomic characterization generated by CPTAC.
239 Whole exome sequencing of 10 pancreatic neuroendocrine tumor patients.
240 Whole-genome sequencing of 98 pancreatic neuroendocrine tumours (PanNETs) and matched normal DNA pairs.
241 Exome and whole genome sequencing of 496 papillary thyroid carcinoma tumor/normal pairs
242 Whole genome or whole exome sequencing on 298 Pediatric Acute Lymphoid Leukemia - Phase II samples. Comprehensive profiling of ALL Phase 2 samples.
TARGET data is intended exclusively for biomedical research using pediatric data (i.e., the research objectives cannot be accomplished using data from adults) that focus on the development of more effective treatments, diagnostic tests, or prognostic markers for childhood cancers. Moreover, TARGET data can be used for research relevant to the biology, causes, treatment and late complications of treatment of pediatric cancers, but is not intended for the sole purposes of methods and/or tool development (please see Using TARGET Data section of the OCG website). If you are interested in using TARGET data for publication or other research purposes, you must follow the TARGET Publication Guidelines.
TARGET data is intended exclusively for biomedical research using pediatric data (i.e., the research objectives cannot be accomplished using data from adults) that focus on the development of more effective treatments, diagnostic tests, or prognostic markers for childhood cancers. Moreover, TARGET data can be used for research relevant to the biology, causes, treatment and late complications of treatment of pediatric cancers, but is not intended for the sole purposes of methods and/or tool development (please see Using TARGET Data section of the OCG website). If you are interested in using TARGET data for publication or other research purposes, you must follow the TARGET Publication Guidelines. 244 Integrated proteogenomic characterization across major histological types of pediatric brain cancer . We report a comprehensive proteogenomics analysis, including whole-genome sequencing, RNA sequencing, and proteomics and phosphoproteomics profiling, of 218 tumors across 7 histological types of childhood brain cancer: low-grade glioma (n = 93), ependymoma (32), high-grade glioma (25), medulloblastoma (22), ganglio-glioma (18), craniopharyngioma (16), and atypical teratoid rhabdoid tumor (12). Proteomics data identify common biological themes that span histological boundaries, suggesting that treatments used for one histological type may be applied effectively to other tumors sharing similar proteomics features. Immune landscape characterization reveals diverse tumor microenvironments across and within diagnoses. Proteomics data further reveal functional effects of somatic mutations and copy number variations (CNVs) not evident in transcriptomics data. 245 Whole exome sequencing of 96 pediatric Ewing Sarcoma tumors and 11 cell lines. 246 Whole genome or whole exome sequencing on 1089 NBL samples. Comprehensive profiling of 1089 NBL samples.TARGET data is intended exclusively for biomedical research using pediatric data (i.e., the research objectives cannot be accomplished using data from adults) that focus on the development of more effective treatments, diagnostic tests, or prognostic markers for childhood cancers. Moreover, TARGET data can be used for research relevant to the biology, causes, treatment and late complications of treatment of pediatric cancers, but is not intended for the sole purposes of methods and/or tool development (please see Using TARGET Data section of the OCG website). If you are interested in using TARGET data for publication or other research purposes, you must follow the TARGET Publication Guidelines.
247 Whole-genome/exome sequencing of 961 Pediatric Cancer samples. Data generated from Pfister Lab & DKFZ/German Cancer Consortium. 248 Whole exome sequencing of 103 samples (88 with matched normals) from 88 high-risk pediatric cancer patients. 249 Whole-exome sequencing of 261 patient derived xenografts (PDXs) samples from high-risk childhood cancers (with no matched normals). Website: PPTC 250 Whole-genome sequencing 72 patients with Rhabdoid Tumor. Comprehensive profiling of 72 patients with Rhabdoid Tumor.TARGET data is intended exclusively for biomedical research using pediatric data (i.e., the research objectives cannot be accomplished using data from adults) that focus on the development of more effective treatments, diagnostic tests, or prognostic markers for childhood cancers. Moreover, TARGET data can be used for research relevant to the biology, causes, treatment and late complications of treatment of pediatric cancers, but is not intended for the sole purposes of methods and/or tool development (please see Using TARGET Data section of the OCG website). If you are interested in using TARGET data for publication or other research purposes, you must follow the TARGET Publication Guidelines.
251 Whole-exome sequencing of 657 Wilms' tumor samples. Comprehensive profiling of 657 Wilms' Tumor samples.TARGET data is intended exclusively for biomedical research using pediatric data (i.e., the research objectives cannot be accomplished using data from adults) that focus on the development of more effective treatments, diagnostic tests, or prognostic markers for childhood cancers. Moreover, TARGET data can be used for research relevant to the biology, causes, treatment and late complications of treatment of pediatric cancers, but is not intended for the sole purposes of methods and/or tool development (please see Using TARGET Data section of the OCG website). If you are interested in using TARGET data for publication or other research purposes, you must follow the TARGET Publication Guidelines.
252 Whole-exome sequencing of 178 Pheochromocytoma or Paraganglioma tumor/normal pairs. 253 TCGA Pheochromocytoma and Paraganglioma. Source data from GDAC Firehose. Previously known as TCGA Provisional. 254 Pheochromocytoma and Paraganglioma TCGA PanCancer data. The original data is here. The publications are here. 255 Whole-genome sequencing of 96 pilocytic astrocytoma tumor/normal pairs. Conducted by the International Cancer Genome Consortium (ICGC) PedBrain Tumor Project. 256 Whole-exome sequencing of 22 malignant pleural mesotheliomas (PLMESO) tumor/normal pairs. 257 Targeted sequencing of 341 cancer genes from 117 patient-derived PDTCs and ATCs 258 Exome sequencing of 19 immunocompetent primary central nervous system lymphoma (PCNSL) samples. 259 Whole genome sequencing of 57 prostate tumor and matches normal tissues. 260 Whole-exome sequencing of 112 prostate adenocarcinomas and matched normal samples. Generated by Levi Garraway's lab at the Broad Institute and Mark Rubin's lab at Cornell. 261 Whole-genome/exome sequencing of 477 prostate samples from CPC-GENE and public data sets, including TCGA-PRAD. 262 Whole-exome sequencing, array comparative genomic hybridization (CGH) and RNA transcript profiling of 176 tumors from 63 patients with disseminated prostate cancer with matched normals. 263 Targeted sequencing of 1465 prostate adenocarcinoma tumor/normal pairs via MSK-IMPACT. 264 Comprehensive profiling of 218 prostate tumors (181 primaries, 37 metastases) and 14 prostate cancer cell lines and xenografts. MSKCC Prostate Oncogenome Project.